ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,08165
0,00%
Bitcoin
69.264,94
-0,10%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NYSE
  6. AbbVie Inc (ABBV)

  7. AbbVie Inc (ABBV) News

ABBV

AbbVie (ABBV)

AbbVie Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NYSE:ABBV
DatumZeitQuelleÜberschriftSymbolFirma
06/06/202414h45PR Newswire (US)AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRα) Expressing Platinum-Sensitive Ovarian CancerNYSE:ABBVAbbVie Inc
06/06/202414h30PR Newswire (US)SkinMedica® Celebrates 25 Years of Empowering Radiant SkinNYSE:ABBVAbbVie Inc
06/06/202414h00PR Newswire (US)AbbVie Launches First-of-its-Kind Contest to Empower People Living with Migraine in their CareersNYSE:ABBVAbbVie Inc
05/06/202415h00PR Newswire (US)AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383NYSE:ABBVAbbVie Inc
04/06/202414h30PR Newswire (US)RINVOQ® (upadacitinib) Now Available for Pediatric Patients Two Years and Older with Polyarticular Juvenile Idiopathic Arthritis and Psoriatic ArthritisNYSE:ABBVAbbVie Inc
04/06/202414h05PR Newswire (US)Refer Your Friends to Allē, the Loyalty Rewards Program by Allergan Aesthetics, and Earn $50NYSE:ABBVAbbVie Inc
03/06/202414h30PR Newswire (US)AbbVie to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
31/05/202422h05Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:ABBVAbbVie Inc
31/05/202408h00PR Newswire (US)AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Moderately to Severely Active Ulcerative ColitisNYSE:ABBVAbbVie Inc
28/05/202414h00PR Newswire (US)AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative Antibody-Drug Conjugate (ADC) PlatformNYSE:ABBVAbbVie Inc
23/05/202422h05PR Newswire (US)AbbVie Completes Acquisition of Landos BiopharmaNYSE:ABBVAbbVie Inc
17/05/202413h30PR Newswire (US)AbbVie Presents New Data Supporting Leading Gastroenterology Portfolio at 2024 Digestive Disease Week®NYSE:ABBVAbbVie Inc
13/05/202414h39PR Newswire (US)AbbVie and Gilgamesh Pharmaceuticals Announce Collaboration and Option-to-License Agreement to Develop Next-Generation Therapies for Psychiatric DisordersNYSE:ABBVAbbVie Inc
08/05/202423h00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NYSE:ABBVAbbVie Inc
08/05/202414h00PR Newswire (Canada)QULIPTA(MC) (atogépant) est maintenant approuvé par Santé Canada pour la prévention de la migraine chronique chez les adultesNYSE:ABBVAbbVie Inc
08/05/202414h00PR Newswire (Canada)QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in AdultsNYSE:ABBVAbbVie Inc
08/05/202402h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
08/05/202400h31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
08/05/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
08/05/202400h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
06/05/202414h00PR Newswire (US)AbbVie to Present at the Bank of America Securities Healthcare ConferenceNYSE:ABBVAbbVie Inc
26/04/202413h47IH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
26/04/202413h35PR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/04/202414h00PR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
23/04/202414h00PR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
18/04/202414h31PR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
12/04/202413h30PR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
09/04/202414h00PR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
04/04/202414h00PR Newswire (US)AbbVie to Host First-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
03/04/202414h30PR Newswire (US)Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®NYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV

Kürzlich von Ihnen besucht

USOTC
FYMNF
Finlay Minerals (QB)
COIN
RHPETH
Rhamos Properties
USOTC
MNSKY
Mony (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten